Found: 19
Select item for more details and to access through your institution.
Contribution of the Rv2333c efflux pump (the Stp protein) from Mycobacterium tuberculosis to intrinsic antibiotic resistance in Mycobacterium bovis BCG.
- Published in:
- Journal of Antimicrobial Chemotherapy (JAC), 2007, v. 59, n. 3, p. 544
- By:
- Publication type:
- Article
Characterization of tetracycline resistance mediated by the efflux pump Tap from Mycobacterium fortuitum.
- Published in:
- Journal of Antimicrobial Chemotherapy (JAC), 2006, v. 57, n. 2, p. 252
- By:
- Publication type:
- Article
The Veterinary Anti-Parasitic Selamectin Is a Novel Inhibitor of the Mycobacterium tuberculosis DprE1 Enzyme.
- Published in:
- International Journal of Molecular Sciences, 2022, v. 23, n. 2, p. 771, doi. 10.3390/ijms23020771
- By:
- Publication type:
- Article
Challenges faced by multi-displinary new investigators on addressing grand challenges in global health.
- Published in:
- Globalization & Health, 2014, v. 10, n. 1, p. 1, doi. 10.1186/1744-8603-10-27
- By:
- Publication type:
- Article
Challenges faced by multidisplinary new investigators on addressing grand challenges in global health.
- Published in:
- 2014
- By:
- Publication type:
- journal article
Repurposing β-Lactams for the Treatment of Mycobacterium kansasii Infections: An In Vitro Study.
- Published in:
- Antibiotics (2079-6382), 2023, v. 12, n. 2, p. 335, doi. 10.3390/antibiotics12020335
- By:
- Publication type:
- Article
Repurposing Avermectins and Milbemycins against Mycobacteroides abscessus and Other Nontuberculous Mycobacteria.
- Published in:
- Antibiotics (2079-6382), 2021, v. 10, n. 4, p. 381, doi. 10.3390/antibiotics10040381
- By:
- Publication type:
- Article
Selamectin Is the Avermectin with the Best Potential for Buruli Ulcer Treatment.
- Published in:
- PLoS Neglected Tropical Diseases, 2015, v. 9, n. 8, p. 1, doi. 10.1371/journal.pntd.0003996
- By:
- Publication type:
- Article
Repurposing clinically approved cephalosporins for tuberculosis therapy.
- Published in:
- Scientific Reports, 2016, p. 34293, doi. 10.1038/srep34293
- By:
- Publication type:
- Article
Evaluation of critical parameters in the hollow‐fibre system for tuberculosis: A case study of moxifloxacin.
- Published in:
- British Journal of Clinical Pharmacology, 2024, v. 90, n. 7, p. 1711, doi. 10.1111/bcp.16068
- By:
- Publication type:
- Article
Triple oral beta-lactam containing therapy for Buruli ulcer treatment shortening.
- Published in:
- PLoS Neglected Tropical Diseases, 2019, v. 13, n. 1, p. 1, doi. 10.1371/journal.pntd.0007126
- By:
- Publication type:
- Article
Editorial: Ivermectin and COVID-19: Keeping Rigor in Times of Urgency.
- Published in:
- American Journal of Tropical Medicine & Hygiene, 2020, v. 102, n. 6, p. 1156, doi. 10.4269/ajtmh.20-0271
- By:
- Publication type:
- Article
Amoxicillin/clavulanate in combination with rifampicin/clarithromycin is bactericidal against Mycobacterium ulcerans.
- Published in:
- PLoS Neglected Tropical Diseases, 2024, v. 18, n. 4, p. 1, doi. 10.1371/journal.pntd.0011867
- By:
- Publication type:
- Article
Measurements of the in vitro anti-mycobacterial activity of ivermectin are method-dependent-authors' response.
- Published in:
- 2014
- By:
- Publication type:
- Journal Article
Measurements of the in vitro anti-mycobacterial activity of ivermectin are method-dependent.
- Published in:
- 2014
- By:
- Publication type:
- Journal Article
Measurements of the in vitro anti-mycobacterial activity of ivermectin are method-dependent—authors' response.
- Published in:
- 2014
- By:
- Publication type:
- Letter to the Editor
Measurements of the in vitro anti-mycobacterial activity of ivermectin are method-dependent.
- Published in:
- 2014
- By:
- Publication type:
- Letter to the Editor
In vitro synergy screens of FDA-approved drugs reveal novel zidovudine- and azithromycin-based combinations with last-line antibiotics against Klebsiella pneumoniae.
- Published in:
- Scientific Reports, 2023, v. 13, n. 1, p. 1, doi. 10.1038/s41598-023-39647-9
- By:
- Publication type:
- Article
In vitro synergy screens of FDA-approved drugs reveal novel zidovudine- and azithromycin-based combinations with last-line antibiotics against Klebsiella pneumoniae.
- Published in:
- Scientific Reports, 2023, v. 13, n. 1, p. 1, doi. 10.1038/s41598-023-39647-9
- By:
- Publication type:
- Article